Pediatric Asthma Treatment Market Report 2026

The pediatric asthma treatment market size has grown strongly in recent years. It will grow from $11.65 billion in 2025 to $12.31 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to limited availability of pediatric-specific asthma medications, reliance on hospital-based treatment, growing prevalence of childhood asthma, increasing awareness among caregivers, adoption of conventional inhalers and short-acting beta agonists.

The pediatric asthma treatment market size is expected to see strong growth in the next few years. It will grow to $15.14 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to development of biologics and combination therapies, integration of digital health monitoring devices, expansion of home care services, rising online pharmacy adoption, increasing regulatory approvals for pediatric asthma drugs. Major trends in the forecast period include increasing adoption of personalized pediatric asthma therapies, rising use of biologic treatments and combination inhalers, growth in home care and remote patient monitoring, expansion of online and retail pharmacy distribution channels, focus on early diagnosis and preventive asthma management.

The rising prevalence of respiratory infections is expected to drive growth in the pediatric asthma treatment market in the coming years. Respiratory infections are illnesses caused by viruses, bacteria, or other pathogens that affect the respiratory tract, including the nose, throat, airways, and lungs. Their increasing prevalence is largely attributed to rising air pollution, as exposure to pollutants like particulate matter and nitrogen dioxide weakens the respiratory system, making individuals more susceptible to infections. Pediatric asthma treatments help reduce the frequency and severity of respiratory infections by improving airway function and minimizing inflammation, which lowers vulnerability to infectious triggers. For instance, in June 2024, the Australian Institute of Health and Welfare reported that chronic obstructive pulmonary disease accounted for 3.6% of the total disease burden in 2023 and represented 50% of the overall burden of respiratory conditions. Therefore, the rising prevalence of respiratory infections is propelling growth in the pediatric asthma treatment market.

Key companies in the pediatric asthma treatment market are focusing on innovative therapies such as monoclonal antibodies to specifically target and reduce airway inflammation in children. Monoclonal antibodies are laboratory-engineered proteins that mimic the immune system’s ability to neutralize harmful cells or substances. For example, in April 2024, AstraZeneca PLC, a UK-based pharmaceutical company, received U.S. FDA approval for FASENRA (benralizumab) as an add-on maintenance treatment for children aged 6-11 years with severe eosinophilic asthma. FASENRA reduces asthma exacerbations by targeting and eliminating eosinophils and is administered via subcutaneous injection every four weeks for the first three doses, then every eight weeks, with pediatric dosing adjusted by body weight.

In January 2025, Molex LLC, a US-based consumer electronics company, acquired Vectura Group plc for an undisclosed amount. Through this acquisition, Molex aims to expand its inhalation drug delivery capabilities and strengthen its position in providing end-to-end solutions for respiratory and non-respiratory therapies. Vectura Group Services Limited, based in the UK, is developing a pediatric asthma treatment, a smart budesonide delivery system known as VR647.

Major companies operating in the pediatric asthma treatment market are Pfizer Inc., Merck And Co Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Genentech Inc., Chiesi Farmaceutici S.p.A, Dr. Reddy's Laboratories Ltd, Cipla Ltd, Lupin Limited, Zydus Lifesciences Ltd.

North America was the largest region in the pediatric asthma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric asthma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pediatric asthma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the pediatric asthma treatment market by increasing the cost of imported active pharmaceutical ingredients (APIs) and specialized inhaler devices. Segments such as biologics, combination inhalers, and short-acting beta agonists are particularly impacted, with regions like North America and Asia-Pacific facing higher import duties. This has led to increased treatment costs and supply chain disruptions. Positively, tariffs are encouraging local production of pediatric asthma drugs, innovation in inhaler technologies, and investment in domestic pharmaceutical manufacturing capacities.

The pediatric asthma treatment market research report is one of a series of new reports that provides pediatric asthma treatment market statistics, including pediatric asthma treatment industry global market size, regional shares, competitors with a pediatric asthma treatment market share, detailed pediatric asthma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric asthma treatment industry. This pediatric asthma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pediatric asthma treatment refers to the medical management and therapeutic interventions aimed at controlling and alleviating asthma symptoms in children. It involves the use of medications, lifestyle adjustments, and monitoring strategies to reduce inflammation, prevent asthma attacks, and improve respiratory function.

The main types of pediatric asthma treatment include long-term control medications, quick-relief medications, and other therapies. Long-term control medications are taken daily over an extended period to reduce inflammation, prevent symptoms, and maintain stable lung function. This category includes inhaled corticosteroids, long-acting beta agonists, leukotriene modifiers, antihistamines, and biologics. These medications are administered through various routes, including oral, nasal, and injectable forms. They are distributed via hospital pharmacies, retail pharmacies, and online pharmacies, and are used across multiple settings, such as hospitals, clinics, homecare, and other healthcare environments.

The pediatric asthma treatment market consists of sales of nebulizers and soft-mist inhalers, oral medications, biologic injectables, and smart monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.